To investigate the role of PDCD11 overexpression in representative p53‐mutant cancer cases, we performed Kaplan‐Meier survival analyses.[13] High‐level PDCD11 shortened the overall survival (OS), recurrence‐free survival (RFS), and distant metastasis‐free survival (DMFS) in patients with p53‐mutant breast cancer with lymph node positivity within 5 years (Figure 1C–E), as well as the 5‐year OS and RFS of p53‐mutant colon cancer patients (Stage T1‐T3) (Figure 1F,G), revealing that PDCD11 abundance is closely and positively correlated. The gene discussed is PDCD11; the disease is breast cancer.